Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03263091 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
A Phase 3 study, sponsored by Kyntra Bio.
- Terminated
- Registry status
- Phase 3
- Development phase
- 184
- Enrollment target
NCT03263091 is a Phase 3 study that was terminated before completion, run by Kyntra Bio. The registered enrollment target is 184 participants.
The verdict
NCT03263091, a Phase 3 study, was terminated before completion, sponsored by Kyntra Bio.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 184 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether FG-4592 is safe and effective in the treatment of anemia in participants with lower risk MDS and low red blood cell transfusion burden.
Interventions
- DRUG Placebo
- DRUG Roxadustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2018-01-29 |
| Est. Completion | 2023-06-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03263091
The ClinicalTrials.gov registry entry for NCT03263091 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03263091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03263091 about?
NCT03263091 is a clinical study titled "Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden". The purpose of this study is to determine whether FG-4592 is safe and effective in the treatment of anemia in participants with lower risk MDS and low red blood cell transfusion burden.
What is the current status of trial NCT03263091?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 184 participants. The study started on 2018-01-29. Estimated completion is 2023-06-20.
What interventions are being tested in trial NCT03263091?
The interventions under investigation include: Placebo (DRUG), Roxadustat (DRUG).
Who is sponsoring clinical trial NCT03263091?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.